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such as BMI, lipid panel, and hepatic panel were not predictive of development of diabetes
subsequent to a pancreatitis episode. Organ failure and etiology also did not predict subsequent DM. Amongst 1013 patients who had received abdominal imaging during or prior
to the index admission, 580 were identified with hepatic steatosis. Interestingly, while
cirrhosis (OR 5.5 [95% CI 2.1-14.5]) was a strong predictor, hepatic steatosis was not
associated with subsequent development of diabetes.
Conclusion Local pancreatic complications (pancreatic necrosis, pseudocyst formation, etc),
recurrent pancreatitis, and current smoking predict subsequent development of diabetes.
This raises the question of whether direct injury to the gland rather than more severe
systemic disease may favor subsequent endocrine dysfunction.

Table 1: Propensity Matching Characteristics

Fr304
HYPERLIPASEMIA DOES NOT CONFER WORSE CLINICAL OUTCOMES IN
A RETROSPECTIVE COHORT OF NOVEL CORONAVIRUS (COVID-19)
PATIENTS
Zaid Imam, Inayat Gill, Bana Antonios, Andrew Aneese, Guarav Kakked, Faisal Kamal,
Bara El Kurdi, Alexandra Halalau
Abstract Background Gastrointestinal manifestations and hyperlipasemia commonly occur
as part of novel coronavirus infection (COVID-19), while data on acute pancreatitis is limited
to case reports. We aimed to study the prevalence of hyperlipasemia and acute pancreatitis
in a large inpatient cohort of COVID-19 patients and their impact on clinical outcomes.
Methods Retrospective chart review of all hospitalized patients with confirmed COVID-19
at an 8-hospital health system in Michigan, USA was performed between February 1,2020
through April 1,2020 with inclusion of patients with obtained lipase levels. Univariate
analyses were performed to evaluate associations between hyperlipasemia and degree of
hyperlipasemia and clinical outcomes of mechanical ventilation, intensive care unit (ICU)
admission, and mortality. COVID-19 attributed pancreatitis was defined as an episode
fulfilling criteria for acute pancreatitis defined earlier, a temporally associated diagnosis of
COVID-19 and an exclusion of the most common etiologies of acute pancreatitis (gallstones,
alcohol use, class IA/IB/II medication (by Badalov classification) use, endoscopic retrograde
pancreatography, or metabolic etiologies (hypercalcemia, hypertriglyceridemia (>1000mg/
dl)). Results Prevalence of hyperlipasemia was 26.6% and of acute pancreatitis 0.33% in
301 patients with COVID-19. Patients with hyperlipasemia were older (p=0.044) and more
likely to have chronic kidney disease (p=0.002) (Table 1). A total of 158 (52.5%) of
patients reported at least one gastrointestinal symptom (abdominal pain, nausea, vomiting
or diarrhea), and the presence of any gastrointestinal symptoms was not associated with the
presence of hyperlipasemia (p=0.790). Neither presence of hyperlipasemia or its severity
stratified into mild (60-120 U/L), moderate (120-180 U/L), and severe (>180 U/L) categories
were associated with increased rates of mechanical ventilation, ICU admission or increased
mortality (Table 2). Acute pancreatitis occurred in two patients of which one case was biliary
in origin. Prevalence of COVID-19 acute pancreatitis in the reported cohort was 0.33%. Of
the other patients with hyperlipasemia, 18 underwent computed tomography of the abdomen
and an intra-abdominal process was identified in only two patients, with colitis identified
in one patient, and ileus in another. Discussion and Conclusions Acute pancreatitis in
COVID-19 patients is rare while hyperlipasemia is common. Hyperlipasemia in patients
with COVID-19 is likely attributed to several non-pancreatic etiologies. Both hyperlipasemia
in this population, and COVID-19 attributed acute pancreatitis do not appear to have
significant impact on patients’ clinical outcomes.

Table 2: Univariate analyses of propensity-matched cohorts
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INTERVAL ANALYSIS OF PREDICTORS OF DIABETES MELLITUS
SUBSEQUENT TO DISCHARGE FOR ACUTE PANCREATITIS
Brent Hiramoto, Cameron Furey, Selena Zhou, Andrew Foong, Lillian Dawit, Aneesa R.
Chowdhury, Rishi Das, Ira Shulman, Mark Goodarzi, Stephen J. Pandol, James L.
Buxbaum
Introduction There is increasing recognition of diabetes mellitus (DM) as a sequelae of
acute pancreatitis. However, the risk factors and mechanism are not well defined. We aim
to characterize the clinical, biochemical, and radiographic features of acute pancreatitis
associated with the subsequent development of diabetes.
Methods We identified patients with subsequent diabetes using our prospective institutional
observational cohort of hospitalized acute pancreatitis patients. The primary outcome was
the development of subsequent diabetes mellitus following the index admission for acute
pancreatitis. This cohort was defined as patients diagnosed with diabetes mellitus following
discharge for acute pancreatitis who had no history of diabetes prior to admission and who
were not diagnosed with DM during the hospitalization. At least nine months of follow up
were available following index hospitalization. We investigated 104 clinical parameters to
assess for potential associations with subsequent diabetes using logistic regression. These
included baseline demographics, metabolic parameters such as BMI, lipid profile, hepatic
panel, comorbidities, recurrent pancreatitis (defined as ≥2 episodes of acute pancreatitis),
severity of the pancreatitis episode (Revised Atlanta Classification), organ failure and development of local complications, which included necrosis, pseudocysts, and organized fluid collections.
Results 1080 unique patients with acute pancreatitis were identified from March 2015
through January 2020 and 306 patients were diagnosed with diabetes through September
2020. Within this cohort, 24 of the patients developed diabetes following discharge from
their index admission for acute pancreatitis; the remainder were diagnosed prior to or in
the course of the admission. Strong predictors for development of diabetes included current
smoking (OR 5.7 [95% CI 2.5-13.2]), local complications (OR 2.5 [95% CI 1.1-5.8]) and
recurrent pancreatitis (OR 6.4 [95% CI 1.9-22.1](Table 1). Baseline metabolic parameters
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P < 0.0001). One-year all-cause mortality was significantly higher in the ANP cohort (8.2%
vs 5.0%, OR 1.7, 95% CI 1.5-1.9, P < 0.0001).
Conclusion: When comparing propensity-matched cohorts, patients with acute necrotizing
pancreatitis were observed to have significantly higher rates of numerous new psychosocial
outcomes in comparison to patients with acute pancreatitis without necrosis within the
year following onset of the disease. Health care providers should aim to incorporate basic
psychological and quality of life assessments during visits with patients diagnosed with acute
necrotizing pancreatitis in order to improve psychosocial functioning.
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Discussion: AC in patient with SVT from AP has not been adequately studied. Moreover,
prior mostly small single center observational studies have reported equivalent recanalization
rates with or without AC. Our study did not reveal any significant difference in the outcomes
of patients with SVT in AP with or without AC, suggesting that there may not be any benefit
of using systemic AC in these patients. AC should be considered on a case by case basis;
perhaps in patients with extension of thrombus threatening small bowel ischemia.

Table 1: Comparison of baseline characteristics (demographics, etiology of pancreatitis,
medical co-morbidities and severity of pancreatitis) between the AC and non-AC group.
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UTILITY OF ANTICOAGULATION FOR SPLANCHNIC VEIN THROMBOSIS
FROM ACUTE PANCREATITIS – A NATIONWIDE RETROSPECTIVE
COHORT ANALYSIS
Shaman Dalal, Sherif Saleh, Aakash Desai, Ehsan Chitsaz
Background: Splanchnic vein thrombosis (SVT) is a well-known complication of acute
pancreatitis (AP) that is diagnosed incidentally on abdominal imaging. Extension of the
thrombosis may result in hepatic injury, small bowel ischemia or variceal hemorrhage.
Presently, no consensus exists on the anticoagulation (AC) strategy of incidental SVT in AP
due to inherent risks of systemic AC. The primary aim of our study was to evaluate the
outcomes of AC group compared to non-AC in patients with SVT secondary to AP.
Methods: We performed a retrospective analysis using the IBM Explorys database 5 (19992020), a pooled, national, de-identified clinical database of over 72 million unique patients
from 26 health care networks and 300 hospitals across the United States. Patient populations
were identified using SNOMED and ICD codes. Inclusion criteria for AC group were diagnosis
of SVT (portal vein, mesenteric vein and splenic vein thrombosis) for the first time within
6 months of receiving a diagnosis of AP and receiving AC with Warfarin, Rivaroxaban
or Apixaban. Exclusion criteria were malignancy, atrial fibrillation, stroke, deep venous
thromboembolism and cirrhosis. Primary outcomes evaluated were variceal bleeding, ascites,
small bowel ischemia, small intestinal excision, splenic infarction and liver failure. Odds
ratios with 95% confidence intervals (CI) were calculated and depicted as Forest plots to
compare outcomes between the AC and non-AC groups. Chi-squared test was used to
compare demographics and medical co-morbidities between the two groups.
Results: Out of 104,390 AP patients, a total of 1500 (1.43%) developed SVT. 550 (36.66%)
received anticoagulation (aka AC group) and 950 (63.33%) were in the non-AC group.
Patients with obesity and those with increased BISAP score were more likely to receive AC
(Table 1). Otherwise, there was no significant difference between the two group characteristics. Patients who received anticoagulation had a higher risk of developing GI bleeding (OR
1.39, 95% CI 1.0001-1.94) compared to those who did not.h e risk of varices, ascites, small
intestinal excision, small bowel ischemia, splenic infarction, and liver failure between the
two groups was not statistically significant (Figure 1).

AGA Abstracts

Figure 1: Comparison of primary outcomes with and without anticoagulation(AC) in patients
with splanchnic vein thrombosis secondary to acute pancreatitis.
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POST-CARDIAC SURGERY PANCREATITIS AND ASSOCIATED OUTCOMES:
A SYSTEMIC REVIEW AND META-ANALYSIS
Ishani Shah, Harsh Mehta, Abhishek Bhurwal, Cinthana Kandasamy, Awais Ahmed, Sunil
G. Sheth, Steven D. Freedman
INTRODUCTION: Acute pancreatitis (AP) has been identified as a postoperative complication in patients undergoing cardiac surgery. Several mechanisms such as low cardiac output,
intra-aortic balloon pump usage, use of vasopressors and prolonged cardiopulmonary bypass
time may result in vascular injury to the pancreas. The aim of our study was to identify the
incidence of post-cardiac surgery AP in the published literature and its impact on systemic
complications and mortality.
METHODS: Three independent reviewers performed a comprehensive review of all original
articles published from inception to September 2020, describing the occurrence of postoperative pancreatitis among patients undergoing cardiac surgeries. Primary outcomes were
incidence of AP, necrotizing pancreatitis and pancreatitis-associated multi-organ failure
among these patients. Secondary outcome was mortality rate among these patients with AP
compared to those post-cardiac surgery patients who did not develop AP (control group).
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